Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant

Hepatitis B (HepB) vaccination is the primary means of preventing infections and complications caused by hepatitis B virus (HBV). On February 21, 2018, the Advisory Committee on Immunization Practices (ACIP) recommended Heplisav-B (HepB-CpG), a yeast-derived vaccine prepared with a novel adjuvant, a...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2018-04, Vol.67 (15), p.455-458
Main Authors: Schillie, Sarah, Harris, Aaron, Link-Gelles, Ruth, Romero, José, Ward, John, Nelson, Noele
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Adolescent
Adult
Advisory Committees
Centers for Disease Control and Prevention (U.S.)
Complications and side effects
Full Report
Hepatitis B
Hepatitis B - prevention & control
Hepatitis B vaccines
Hepatitis B Vaccines - administration & dosage
Humans
Immunization Schedule
Infection
Medical research
Practice Guidelines as Topic
Prevention
Randomized Controlled Trials as Topic
United States
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis B (HepB) vaccination is the primary means of preventing infections and complications caused by hepatitis B virus (HBV). On February 21, 2018, the Advisory Committee on Immunization Practices (ACIP) recommended Heplisav-B (HepB-CpG), a yeast-derived vaccine prepared with a novel adjuvant, administered as a 2-dose series (0, 1 month) for use in persons aged ≥18 years. The ACIP Hepatitis Vaccines Work Group conducted a systematic review of the evidence, including data from four randomized controlled trials assessing prevention of HBV infection and six randomized controlled trials assessing adverse events in adults. Seroprotective antibody to hepatitis B surface antigen (anti-HBs) levels were achieved in 90.0%-100.0% of subjects receiving HepB-CpG (Dynavax Technologies Corporation), compared with 70.5%-90.2% of subjects receiving Engerix-B (GlaxoSmithKline Biologicals). The benefits of protection with 2 doses administered over 1 month make HepB-CpG an important option for prevention of HBV.
ISSN:0149-2195
1545-861X
DOI:10.15585/mmwr.mm6715a5